Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


Articles published in Haematologica

Retrieve available abstracts of 94 articles:
HTML format
Text format



Single Articles


    February 2019
  1. HICKS SW, Tarantelli C, Wilhem A, Gaudio E, et al
    The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity than SAR3419 in CD19-positive lymphoma and leukemia models.
    Haematologica. 2019 Feb 7. pii: haematol.2018.211011.
    PubMed     Text format     Abstract available


  2. GONZALEZ-FARRE B, Ramis-Zaldivar JE, Salmeron-Villalobos J, Balague O, et al
    Burkitt-like lymphoma with 11q aberration: A germinal center derived lymphoma genetically unrelated to Burkitt lymphoma.
    Haematologica. 2019 Feb 7. pii: haematol.2018.207928.
    PubMed     Text format     Abstract available


    January 2019
  3. TARANTELLI C, Zhang L, Curti E, Gaudio E, et al
    The BTK inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
    Haematologica. 2019 Jan 24. pii: haematol.2018.214759.
    PubMed     Text format    


  4. TOROSSIAN A, Broin N, Frentzel J, Daugrois C, et al
    Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.
    Haematologica. 2019 Jan 24. pii: haematol.2017.181966.
    PubMed     Text format     Abstract available


  5. QDAISAT A, Al Soud R, Wu CC, Rojas Hernandez CM, et al
    Poor performance of D-Dimer in excluding venous thromboembolism among patients with lymphoma and leukemia.
    Haematologica. 2019 Jan 10. pii: haematol.2018.211466.
    PubMed     Text format    


  6. TAKEUCHI M, Miyoshi H, Asano N, Yoshida N, et al
    Human leukocyte antigen class II expression is a good prognostic factor of adult T-cell leukemia/lymphoma.
    Haematologica. 2019 Jan 10. pii: haematol.2018.205567.
    PubMed     Text format     Abstract available


  7. SILVA A, Bassim S, Sarkozy C, Mottok A, et al
    Convergence of risk prediction models in follicular lymphoma.
    Haematologica. 2019 Jan 3. pii: haematol.2018.209031.
    PubMed     Text format    


  8. SASSE S, Reddemann K, Diepstra A, Borchmann S, et al
    Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment.
    Haematologica. 2019;104:e45-e46.
    PubMed     Text format    


  9. TAYLOR JG, Clear A, Calaminici M, Gribben JG, et al
    Programmed cell death protein-1 (PD1) expression in the microenvironment of classical Hodgkin lymphoma is similar between favorable and adverse outcome and does not enrich over serial relapses with conventional chemotherapy.
    Haematologica. 2019;104:e42-e44.
    PubMed     Text format    


    December 2018
  10. QUALLS D, Abramson JS
    Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma.
    Haematologica. 2018 Dec 20. pii: haematol.2018.195834.
    PubMed     Text format     Abstract available


  11. BELHADJ M, Mansour D, Kaltenbach S, Deau-Fischer B, et al
    T-cell large granular lymphocyte leukemia transformation into aggressive T-cell lymphoma: a report of two cases with molecular characterization.
    Haematologica. 2018 Dec 20. pii: haematol.2018.205542.
    PubMed     Text format    


  12. PHILLIPS AA, Fields PA, Hermine O, Ramos JC, et al
    Mogamulizumab versus investigator choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma.
    Haematologica. 2018 Dec 20. pii: haematol.2018.205096.
    PubMed     Text format     Abstract available


  13. SEYMOUR JF, Marcus R, Davies A, Gallop-Evans E, et al
    Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.
    Haematologica. 2018 Dec 20. pii: haematol.2018.209015.
    PubMed     Text format     Abstract available


  14. ARESU L, Ferraresso S, Marconato L, Cascione L, et al
    New molecular and therapeutic insights into canine diffuse large B cell lymphoma elucidates the role of the dog as a model for human disease.
    Haematologica. 2018 Dec 13. pii: haematol.2018.207027.
    PubMed     Text format    


  15. DELAGE L, Manzoni D, Quinquenet C, Fontaine J, et al
    Molecular analysis of a CD19 negative diffuse large B cell lymphoma.
    Haematologica. 2018 Dec 13. pii: haematol.2018.203521.
    PubMed     Text format    


  16. UCHIDA A, Isobe Y, Asano J, Uemura Y, et al
    Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-protein-expression" lymphoma with MYC and BCL2 rearrangements.
    Haematologica. 2018 Dec 6. pii: haematol.2018.204958.
    PubMed     Text format     Abstract available


    November 2018
  17. RULE S, Dreyling M, Goy A, Hess G, et al
    Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow-up from a pooled analysis.
    Haematologica. 2018 Nov 15. pii: haematol.2018.205229.
    PubMed     Text format    


    October 2018
  18. HAGENBEEK A, Mooij H, Zijlstra J, Lugtenburg P, et al
    Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the Transplant BRaVE study.
    Haematologica. 2018 Oct 31. pii: haematol.2018.196899.
    PubMed     Text format    


  19. BURKHARD R, Keller I, Arambasic M, Juskevicius D, et al
    TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation via NF-kappaB mediated signaling in B-cells.
    Haematologica. 2018 Oct 31. pii: haematol.2018.201590.
    PubMed     Text format     Abstract available


  20. BERGMANN AK, Fataccioli V, Castellano G, Martin-Garcia N, et al
    DNA methylation profiling identifies candidate genes for the pathogenesis of hepatosplenic T-cell lymphoma.
    Haematologica. 2018 Oct 18. pii: haematol.2018.196196.
    PubMed     Text format    


  21. CASAGRANDE N, Borghese C, Visser L, Mongiat M, et al
    CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.
    Haematologica. 2018 Oct 11. pii: haematol.2018.196725.
    PubMed     Text format     Abstract available


  22. EVRARD SM, Pericart S, Grand D, Amara N, et al
    Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and /or BCL6 rearrangements.
    Haematologica. 2018 Oct 11. pii: haematol.2018.198572.
    PubMed     Text format    


    September 2018
  23. KUBOTA-TANAKA M, Osumi T, Miura S, Tsujimoto H, et al
    B-lymphoblastic lymphoma with the TCF3-PBX1 fusion gene.
    Haematologica. 2018 Sep 27. pii: haematol.2018.199885.
    PubMed     Text format    


  24. LEIVONEN SK, Pollari M, Bruck O, Pellinen T, et al
    T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.
    Haematologica. 2018 Sep 20. pii: haematol.2018.200105.
    PubMed     Text format     Abstract available


  25. OCHI Y, Hiramoto N, Yoshizato T, Ono Y, et al
    Clonally related diffuse large B-cell lymphoma and interdigitating dendritic cell sarcoma sharing MYC translocation.
    Haematologica. 2018 Sep 20. pii: haematol.2018.193490.
    PubMed     Text format    


  26. SCHUHMACHER B, Bein J, Rausch T, Benes V, et al
    JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell/histiocyte rich large B-cell lymphoma.
    Haematologica. 2018 Sep 13. pii: haematol.2018.203224.
    PubMed     Text format     Abstract available


  27. STRATI P, Fanale M, Oki Y, Turturro F, et al
    Rituximab with ABVD vs ABVD for advanced stage high-risk classical Hodgkin lymphoma: a randomized phase II study.
    Haematologica. 2018 Sep 6. pii: haematol.2018.199844.
    PubMed     Text format    


  28. EYRE TA, Walter HS, Iyengar S, Follows G, et al
    Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
    Haematologica. 2018 Sep 6. pii: haematol.2018.198812.
    PubMed     Text format    


    August 2018
  29. GRESSIN R, Daguindau N, Tempescul A, Moreau A, et al
    A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first line treatment of older patients with mantle cell lymphoma.
    Haematologica. 2018 Aug 31. pii: haematol.2018.191429.
    PubMed     Text format     Abstract available


  30. KINOSHITA S, Ishida T, Ito A, Narita T, et al
    Cyclin-dependent kinase 9 as a potential specific molecular target in NK cell leukemia/lymphoma.
    Haematologica. 2018 Aug 3. pii: haematol.2018.191395.
    PubMed     Text format     Abstract available


  31. MENSAH AA, Cascione L, Gaudio E, Tarantelli C, et al
    Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma.
    Haematologica. 2018 Aug 3. pii: haematol.2018.191684.
    PubMed     Text format     Abstract available


  32. SASSE S, Reddemann K, Diepstra A, Oschlies I, et al
    Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment.
    Haematologica. 2018 Aug 3. pii: haematol.2018.196279.
    PubMed     Text format    


  33. DE SMEDT R, Peirs S, Morscio J, Matthijssens F, et al
    Preclinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.
    Haematologica. 2018 Aug 3. pii: haematol.2018.199257.
    PubMed     Text format    


  34. MELANI C, Roschewski M, Wilson WH
    End-of-treatment and serial PET imaging has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams et al.
    Haematologica. 2018;103:e382.
    PubMed     Text format    


  35. ADAMS HJA, Kwee TC
    Unproven value of end-of-treatment and serial follow-up FDG-PET in primary mediastinal B-cell lymphoma.
    Haematologica. 2018;103:e380-e381.
    PubMed     Text format    


    July 2018
  36. POLLARI M, Bruck O, Pellinen T, Vahamurto P, et al
    PD-L1+ tumor-associated macrophages and PD-1+ tumor infiltrating lymphocytes predict survival in primary testicular lymphoma.
    Haematologica. 2018 Jul 19. pii: haematol.2018.197194.
    PubMed     Text format     Abstract available


  37. DE CHARETTE M, Houot R
    Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.
    Haematologica. 2018 Jul 13. pii: haematol.2017.184192.
    PubMed     Text format     Abstract available


  38. VILLA D, Sehn LH, Aquino-Parsons C, Tonseth P, et al
    Interim PET-directed therapy in limited stage Hodgkin lymphoma initially treated with ABVD.
    Haematologica. 2018 Jul 12. pii: haematol.2018.196782.
    PubMed     Text format    


  39. ARAF S, Wang J, Ashton-Key M, Korfi K, et al
    Transmission of diffuse large B cell lymphoma by an allogeneic stem-cell transplant.
    Haematologica. 2018 Jul 5. pii: haematol.2018.196907.
    PubMed     Text format    


    June 2018
  40. AMBROSIO MR, Lazzi S, Lo Bello G, Santi R, et al
    MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients.
    Haematologica. 2018 Jun 28. pii: haematol.2018.195958.
    PubMed     Text format    


  41. RECASENS-ZORZO C, Cardesa-Salzmann T, Petazzi P, Ros-Blanco L, et al
    Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.
    Haematologica. 2018 Jun 28. pii: haematol.2017.180505.
    PubMed     Text format     Abstract available


  42. EPSTEIN MM, Rosner B, Breen EC, Batista JL, et al
    Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies.
    Haematologica. 2018 Jun 21. pii: haematol.2017.183236.
    PubMed     Text format     Abstract available


  43. MCPHAIL ED, Maurer MJ, Macon WR, Feldman AL, et al
    Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements.
    Haematologica. 2018 Jun 14. pii: haematol.2018.190157.
    PubMed     Text format     Abstract available


  44. PEREZ-SALVIA M, Aldaba E, Vara Y, Fabre M, et al
    In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma.
    Haematologica. 2018 Jun 7. pii: haematol.2018.189241.
    PubMed     Text format    


    May 2018
  45. ESKELUND CW, Albertsson-Lindblad A, Kolstad A, Laurell A, et al
    Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.
    Haematologica. 2018 May 24. pii: haematol.2018.194399.
    PubMed     Text format    


  46. STORTI S, Spina M, Pesce EA, Salvi F, et al
    Rituximab plus Bendamustine as front line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin's lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi.
    Haematologica. 2018 May 10. pii: haematol.2017.186569.
    PubMed     Text format     Abstract available


  47. TRNENY M, Verhoef G, Dyer MJ, Yehuda DB, et al
    A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.
    Haematologica. 2018 May 10. pii: haematol.2017.168401.
    PubMed     Text format     Abstract available


  48. MELANI C, Advani R, Roschewski M, Walters KM, et al
    End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted-EPOCH-R: A paradigm shift in clinical decision making.
    Haematologica. 2018 May 10. pii: haematol.2018.192492.
    PubMed     Text format     Abstract available


    April 2018
  49. STRATI P, Chihara D, Oki Y, Fayad LE, et al
    A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
    Haematologica. 2018 Apr 5. pii: haematol.2018.187617.
    PubMed     Text format    


  50. KUPPERS R
    CD83 in Hodgkin lymphoma.
    Haematologica. 2018;103:561-562.
    PubMed     Text format    


    March 2018
  51. BELLEI M, Foss FM, Shustov AR, Horwitz SM, et al
    The outcome of peripheral T-cell lymphoma patients failing first line therapy: a report from the prospective, international T-Cell project.
    Haematologica. 2018 Mar 29. pii: haematol.2017.186577.
    PubMed     Text format     Abstract available


  52. HORN H, Kohler C, Witzig R, Kreuz M, et al
    Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2.
    Haematologica. 2018 Mar 22. pii: haematol.2017.181024.
    PubMed     Text format     Abstract available


  53. ALIG S, Jurinovic V, Pastore A, Bararia D, et al
    Impact of age on genetics and treatment efficacy in follicular lymphoma.
    Haematologica. 2018 Mar 15. pii: haematol.2018.187773.
    PubMed     Text format    


  54. MAFFINI E, Anderson LD Jr., Sandmaier BM, Green DJ, et al
    Nonmyeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenstrom macroglobulinemia: Evidence for a graft-versus-lymphoma effect.
    Haematologica. 2018 Mar 15. pii: haematol.2017.184176.
    PubMed     Text format    


    February 2018
  55. BOMBEN R, Ferrero S, D'Agaro T, Dal Bo M, et al
    A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial.
    Haematologica. 2018 Feb 22. pii: haematol.2017.184325.
    PubMed     Text format     Abstract available


  56. BIRSEN R, Willems L, Pallud J, Blanc E, et al
    Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.
    Haematologica. 2018 Feb 22. pii: haematol.2017.185843.
    PubMed     Text format    


  57. RIMSZA LM, Li H, Braziel RM, Spier CM, et al
    Impact of histologic grading on survival in the SWOG S0016 follicular lymphoma cohort.
    Haematologica. 2018 Feb 22. pii: haematol.2017.175059.
    PubMed     Text format     Abstract available


  58. SUEHARA Y, Sakata-Yanagimoto M, Hattori K, Nanmoku T, et al
    Liquid biopsy for the identification of intravascular large B-cell lymphoma.
    Haematologica. 2018 Feb 22. pii: haematol.2017.178830.
    PubMed     Text format     Abstract available


  59. ARVIDSSON G, Henriksson J, Sander B, Wright AP, et al
    Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients
    Haematologica. 2018 Feb 15. pii: haematol.2017.182048.
    PubMed     Text format     Abstract available


  60. SCHOMMERS P, Gillor D, Hentrich M, Wyen C, et al
    Incidence and risk factors for relapses in HIV-associated non-Hodgkin-lymphoma as observed in the German HIV-related lymphoma cohort study.
    Haematologica. 2018 Feb 8. pii: haematol.2017.180893.
    PubMed     Text format     Abstract available


  61. SHALABI H, Kraft IL, Wang HW, Yuan CM, et al
    Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma.
    Haematologica. 2018 Feb 1. pii: haematol.2017.183459.
    PubMed     Text format     Abstract available


    January 2018
  62. FUJI S, Utsunomiya A, Inoue Y, Miyagi T, et al
    Outcomes of patients with relapsed aggressive adult T-cell leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation.
    Haematologica. 2018 Jan 25. pii: haematol.2017.184564.
    PubMed     Text format    


  63. LI Z, Ju X, Lee K, Clarke C, et al
    CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.
    Haematologica. 2018 Jan 19. pii: haematol.2017.178384.
    PubMed     Text format     Abstract available


  64. VAN DEN NESTE E, Andre M, Gastinne T, Stamatoullas A, et al
    Phase II study of oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.
    Haematologica. 2018 Jan 19. pii: haematol.2017.180554.
    PubMed     Text format     Abstract available


  65. JI MM, Huang YH, Huang JY, Wang ZF, et al
    Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.
    Haematologica. 2018 Jan 5. pii: haematol.2017.182444.
    PubMed     Text format     Abstract available


    December 2017
  66. KNORR F, Damm-Welk C, Ruf S, Singh VK, et al
    Blood cytokine concentrations of pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma patients.
    Haematologica. 2017 Dec 14. pii: haematol.2017.177972.
    PubMed     Text format     Abstract available


  67. BOBILLO S, Abrisqueta P, Carpio C, Raheja P, et al
    Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement.
    Haematologica. 2017 Dec 14. pii: haematol.2017.181636.
    PubMed     Text format    


  68. AUNER HW, Iacobelli S, Sbianchi G, Knol-Bout C, et al
    Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.
    Haematologica. 2017 Dec 7. pii: haematol.2017.181339.
    PubMed     Text format     Abstract available


    November 2017
  69. TRACY SI, Habermann TM, Feldman AL, Maurer MJ, et al
    Outcomes among US patients with diffuse large B cell lymphoma are independent of tumor Epstein Barr virus positivity or immunosuppression.
    Haematologica. 2017 Nov 23. pii: haematol.2017.176511.
    PubMed     Text format     Abstract available


  70. COUTRE S, Tedeschi A, Robak T, Barr PM, et al
    Survival adjusting for crossover: phase 3 study of ibrutinib vs chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Haematologica. 2017 Nov 23. pii: haematol.2017.175380.
    PubMed     Text format    


  71. BOSCH M, Akhter A, Chen BE, Mansoor A, et al
    A bio-clinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.
    Haematologica. 2017 Nov 2. pii: haematol.2017.179309.
    PubMed     Text format     Abstract available


  72. NG SB, Chung TH, Kato S, Nakamura S, et al
    EBV-associated primary nodal T/NK-cell lymphoma shows distinct molecular signature and copy number changes.
    Haematologica. 2017 Nov 2. pii: haematol.2017.180430.
    PubMed     Text format     Abstract available


    October 2017
  73. RUDELIUS M, Rosenfeldt MT, Leich E, Rauert-Wunderlich H, et al
    Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.
    Haematologica. 2017 Oct 27. pii: haematol.2017.177162.
    PubMed     Text format     Abstract available


  74. LANDMANN E, Burkhardt B, Zimmermann M, Meyer U, et al
    Results and conclusions of the European Intergroup EURO-LB02 Trial in children and adolescents with lymphoblastic lymphoma.
    Haematologica. 2017 Oct 5. pii: haematol.2015.139162.
    PubMed     Text format     Abstract available


    September 2017
  75. YOUNES A, Salles G, Martinelli G, Bociek RG, et al
    Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed and refractory non-Hodgkin lymphoma.
    Haematologica. 2017 Sep 29. pii: haematol.2017.169656.
    PubMed     Text format     Abstract available


  76. LUGTENBURG P, Avivi I, Berenschot H, Ilhan O, et al
    Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.
    Haematologica. 2017 Sep 21. pii: haematol.2017.173583.
    PubMed     Text format     Abstract available


  77. EICHENAUER DA, Becker I, Monsef I, Chadwick N, et al
    Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials.
    Haematologica. 2017 Sep 14. pii: haematol.2017.167478.
    PubMed     Text format     Abstract available


    August 2017
  78. OKI Y, Kelly KR, Flinn I, Patel MR, et al
    CUDC-907 in relapsed/refractory diffuse Large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase 1 trial.
    Haematologica. 2017 Aug 31. pii: haematol.2017.172882.
    PubMed     Text format     Abstract available


  79. VIDAL-CRESPO A, Rodriguez V, Matas-Cespedes A, Lee E, et al
    The BTK inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on the NF-kappaB mutational status.
    Haematologica. 2017 Aug 24. pii: haematol.2017.168930.
    PubMed     Text format    


  80. BROCCOLI A, Pellegrini C, Di Rocco A, Puccini B, et al
    Italian real life experience with brentuximab vedotin: results of a large observational study on 40 relapsed/refractory systemic anaplastic large cell lymphoma.
    Haematologica. 2017 Aug 3. pii: haematol.2017.171355.
    PubMed     Text format     Abstract available


    July 2017
  81. MONDELAERS V, Suciu S, De Moerloose B, Ferster A, et al
    Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
    Haematologica. 2017 Jul 27. pii: haematol.2017.165845.
    PubMed     Text format     Abstract available


  82. JALLADES L, Baseggio L, Sujobert P, Huet S, et al
    Exome sequencing identifies recurrent BCOR gene alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma.
    Haematologica. 2017 Jul 27. pii: haematol.2016.160192.
    PubMed     Text format     Abstract available


  83. JAIS JP, Molina TJ, Ruminy P, Gentien D, et al
    Reliable subtype classification of diffuse large B-Cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay.
    Haematologica. 2017 Jul 4. pii: haematol.2017.166827.
    PubMed     Text format    


  84. FERRERO S, Dreyling M
    Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?
    Haematologica. 2017;102:1133-1136.
    PubMed     Text format    


    June 2017
  85. VAN DE KROGT JA, Vanden Bempt M, Finalet Ferreiro J, Mentens N, et al
    ALK-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.
    Haematologica. 2017 Jun 28. pii: haematol.2016.146571.
    PubMed     Text format     Abstract available


  86. EHRENTRAUT S, Nagel S, Pommerenke C, Dirks WG, et al
    Peripheral T-cell lymphoma cell line T8ML-1 highlights conspicuous targeting of PVRL2 by t(14;19)(q11.2;q13.3).
    Haematologica. 2017 Jun 28. pii: haematol.2017.168203.
    PubMed     Text format    


  87. BRON D, Aurer I, Andre MPE, Bonnet C, et al
    Unmet needs in the scientific approach to older patients with lymphoma.
    Haematologica. 2017;102:972-975.
    PubMed     Text format    


    May 2017
  88. CAMPOS-MARTIN Y, Martinez N, Martinez-Lopez A, Cereceda L, et al
    Clinical and diagnostic relevance of NOTCH2 and KLF2 mutations in splenic marginal zone lymphoma.
    Haematologica. 2017 May 18. pii: haematol.2016.161711.
    PubMed     Text format    


  89. DAVID A, Arnaud N, Fradet M, Lascaux H, et al
    c-Myc dysregulation is a co-transforming event for nuclear factor-kappaB activated B cells.
    Haematologica. 2017;102:883-894.
    PubMed     Text format     Abstract available


    April 2017
  90. STEVENS WBC, Mendeville M, Redd R, Clear AJ, et al
    Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: A study by the Lunenburg Lymphoma Biomarker Consortium.
    Haematologica. 2017 Apr 14. pii: haematol.2017.165415.
    PubMed     Text format     Abstract available


  91. NOBLE RA, Bell N, Blair H, Sikka A, et al
    Inhibition of monocarboxylate transporter 1 by AZD3965 as a novel therapeutic approach for the treatment of diffuse large B-cell lymphoma and Burkitt lymphoma.
    Haematologica. 2017 Apr 6. pii: haematol.2016.163030.
    PubMed     Text format     Abstract available


  92. BI C, Zhang X, Lu T, Zhang X, et al
    Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas.
    Haematologica. 2017;102:755-764.
    PubMed     Text format     Abstract available


    March 2017
  93. FUJI S, Yamaguchi T, Inoue Y, Utsunomiya A, et al
    Development of a modified prognostic index of patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: a possible risk-adapted management strategies including allogeneic transplantation.
    Haematologica. 2017 Mar 24. pii: haematol.2017.164996.
    PubMed     Text format     Abstract available


  94. DENG AL, Kim YR, Lichtenstein EA, O'Connor OA, et al
    Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B cell lymphoma leg type with mutant MYD88 and wildtype CD79.
    Haematologica. 2017 Mar 24. pii: haematol.2016.161893.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: